Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Pancreatic Cancer Treatment Benefit-Cost Analysis

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Oct 13, 2022 1:24pm

170 Views

Post# 35022804

RE:RE:Pancreatic Cancer Treatment Benefit-Cost Analysis

Yes callahan the hedge fund that you work for is manipulating this stock and has made this calculation. This is the reason why it has been trying to squeeze the small investor out of the stock - but didn't calculate that the small investor is much better informed than this hedge fund "assumed". Now do you have anything of value to post here other than your boss's "schmear"?

<< Previous

Bullboard Posts

Next >>

Morning Market Outlook for Sept. 20, 2024